NAV

Eflepedocokin alfa

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Eflepedocokin alfa
DrugBank Accession Number
DB16366
Background

Eflepedocokin alfa is a recombinant IL-22-Fc fusion protein manufactured in Chinese hamster ovary cells that is composed of 2 human interleukin 22 (IL-22) molecules linked to an immunoglobulin constant region (IgG2-Fc).1,2 It is being developed by Evive Biotech (previously known as Generon BioMed Inc).3

Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins
Protein Chemical Formula
Not Available
Protein Average Weight
Not Available
Sequences
Not Available
Synonyms
  • F-652 (RECOMBINANT FUSION PROTEIN CONSISTING OF TWO HUMAN INTERLEUKIN-22 (IL-22) MOLECULES LINKED TO AN IMMUNOGLOBULIN CONSTANT REGION (IGG2-FC))
  • IL-22 DIMER F-652
  • IL-22 fusion protein
  • RECOMBINANT HUMAN INTERLEUKIN-22 IGG2-FC
External IDs
  • F 652
  • F-652
  • F652
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

F-652 incorporates human interleukin 22’s (IL-22) natural epithelial cell growth-promoting activity as IL-22 plays critical roles in promoting tissue repair and suppressing bacterial infection.1,2 F-652 is currently being investigated against acute graft vs host disease, acute alcoholic hepatitis, inflammatory diseases, organ injuries, eventual fatal organ failures, and COVID-19.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
ZQ9E6EX2JE
CAS number
Not Available

References

General References
  1. Tang KY, Lickliter J, Huang ZH, Xian ZS, Chen HY, Huang C, Xiao C, Wang YP, Tan Y, Xu LF, Huang YL, Yan XQ: Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol. 2019 May;16(5):473-482. doi: 10.1038/s41423-018-0029-8. Epub 2018 Apr 18. [Article]
  2. Evive Biotech: F-652 [Link]
  3. BioSpectrum: Evive Biotech unveiled as the new corporate brand for Generon Biomed [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedTreatmentCoronavirus Disease 2019 (COVID‑19)1
2WithdrawnTreatmentCoronavirus Disease 2019 (COVID‑19) / COVID-19 Pneumonia1
1, 2CompletedTreatmentAcute Graft-Versus-Host Disease (GVHD)1
1, 2CompletedTreatmentAlcoholic Hepatitis (AH)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 18, 2020 15:25 / Updated at September 30, 2023 19:52